Erdosteine is a mucolytic drug whose metabolization gives rise to an active metabolite with an SH group (Met I), which reduces neutrophil release of reactive oxygen species and the peroxynitrite generated by the reaction of superoxide anion with nitric oxide, thus disrupting the phlogogenic loop sustained by activated neutrophils. Elastase, a serine proteinase released by activated human neutrophils, can degrade a wide variety of biomacromols. including elastin and is considered to be pivotal in the pathogenesis of respiratory tract inflammation. The aim of this study was to examine whether, in addn. to reducing the generation of free radicals, Met I can also interfere with the human neutrophil release of elastase. After the neutrophils were incubated with increasing amts. of Met I (1.25, 2.5, 5, 10, 20 mg/mL), elastase exocytosis was initiated by fMLP and measured using MeO-Suc-Ala-Ala-Pro-Val-MCA. The results showed that Met I significantly inhibits fMLP-induced elastase release by neutrophils in a concn.-dependent manner from 2.5 to 20 mg/mL. Our findings may be clin. relevant because the inhibitory effects were obtained at Met I concns. that are achievable in the clin. setting. By reducing elastase and oxidant radical release (two major components of the inflammatory process), Met I have clin. useful anti-inflammatory effects.

Effect of metabolite I of erdosteine on the release of human neutrophil elastase / P. Braga, M. Dal Sasso, M. Culici, P. Verducci, R. Lo Verso, L. Marabini. - In: PHARMACOLOGY. - ISSN 0031-7012. - 77:3(2006), pp. 150-154.

Effect of metabolite I of erdosteine on the release of human neutrophil elastase

P. Braga
Primo
;
L. Marabini
Ultimo
2006

Abstract

Erdosteine is a mucolytic drug whose metabolization gives rise to an active metabolite with an SH group (Met I), which reduces neutrophil release of reactive oxygen species and the peroxynitrite generated by the reaction of superoxide anion with nitric oxide, thus disrupting the phlogogenic loop sustained by activated neutrophils. Elastase, a serine proteinase released by activated human neutrophils, can degrade a wide variety of biomacromols. including elastin and is considered to be pivotal in the pathogenesis of respiratory tract inflammation. The aim of this study was to examine whether, in addn. to reducing the generation of free radicals, Met I can also interfere with the human neutrophil release of elastase. After the neutrophils were incubated with increasing amts. of Met I (1.25, 2.5, 5, 10, 20 mg/mL), elastase exocytosis was initiated by fMLP and measured using MeO-Suc-Ala-Ala-Pro-Val-MCA. The results showed that Met I significantly inhibits fMLP-induced elastase release by neutrophils in a concn.-dependent manner from 2.5 to 20 mg/mL. Our findings may be clin. relevant because the inhibitory effects were obtained at Met I concns. that are achievable in the clin. setting. By reducing elastase and oxidant radical release (two major components of the inflammatory process), Met I have clin. useful anti-inflammatory effects.
Erdosteine; fMLP; Inhibitory effects; Met I; Neutrophil elastase
Settore BIO/14 - Farmacologia
2006
http://content.karger.com/produktedb/produkte.asp?typ=fulltext&file=PHA2006077003150
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/26767
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 7
social impact